RxDoctor Payments Data

Melissa Iglesias, DO

Ophthalmology · Palm Beach Gardens, FLNPI 1225112634

Payments from drug & device makers

$8,754in general payments, 2019–2025

Across 133 payments — averaging $65.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Mallinckrodt Hospital Products Inc.$804
  • AbbVie$683
  • Amgen$619
  • Tarsus Pharmaceuticals, Inc.$564
  • Aerie Pharmaceuticals, Inc.$503
  • plus $3K from 24 others

What the payments were for

  • Travel & lodging$1,22514%
  • Food & beverage$7,48285%
  • Education$100%
  • Gifts$370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,754 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$96,525
Medicare patients
208
Services billed
758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$42,063
IlevroNepafenac67$24,215
XdemvyLotilaner13$23,971
XiidraLifitegrast26$18,953
CombiganBrimonidine Tartrate/Timolol55$16,550
LumiganBimatoprost54$16,304
RhopressaNetarsudil Mesylate43$15,116
MieboPerfluorohexyloctane/Pf18$13,673
Prednisolone Acetate136$4,330
Latanoprost453$3,047
Bromfenac Sodium15$2,572
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat153$2,478
MoxifloxacinMoxifloxacin Hcl115$2,134
Travoprost24$2,118
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$683$74,917169 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$174$32,62544 claims
NovartisIlevro$21$24,21567 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$564$23,97113 claims
Aerie Pharmaceuticals, Inc.Rhopressa$503$15,11643 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →